Drug research

nab-paclitaxel

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Abraxane

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaNCT06390059	NVCR	Phase 2	Completed	2025-11-18Actual
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCNCT03257033	RenovoRx	Phase 3	Recruiting	2027-06Estimated
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320	RVMD	Phase 3	Active not recruiting	2026-06Estimated
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07491445	RVMD	Phase 3	Recruiting	2028-06Estimated

NVCRCompletedPrimary completion: 2025-11-18 · Actual

Trial details

RenovoRxRecruitingPrimary completion: 2027-06 · Estimated

Trial details

RVMDActive not recruitingPrimary completion: 2026-06 · Estimated

Trial details

RVMDRecruitingPrimary completion: 2028-06 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.